Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
11.11
+1.11 (11.10%)
Dec 20, 2024, 4:00 PM EST - Market closed
Artiva Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 2.6 | 33.49 | 4.93 | 2 | - | - |
| Revenue Growth (YoY) | -43.11% | 579.21% | 146.30% | - | - | - |
| Gross Profit | 2.6 | 33.49 | 4.93 | 2 | - | - |
| Selling, General & Admin | 15.42 | 13.91 | 20.78 | 12.86 | 4.43 | 2.09 |
| Research & Development | 48.16 | 50.25 | 43.98 | 42.41 | 13.85 | 1.32 |
| Operating Expenses | 63.59 | 64.16 | 64.76 | 55.27 | 18.27 | 3.41 |
| Operating Income | -60.99 | -30.67 | -59.83 | -53.27 | -18.27 | -3.41 |
| Interest Expense | - | - | - | - | -0.2 | -0.26 |
| Interest & Investment Income | 3.76 | 2.54 | 1.29 | - | 0 | 0.03 |
| Other Non Operating Income (Expenses) | -3.87 | -0.41 | -0.2 | -18.55 | 0.48 | -0.7 |
| EBT Excluding Unusual Items | -61.1 | -28.55 | -58.74 | -71.83 | -17.99 | -4.35 |
| Gain (Loss) on Sale of Investments | -0.1 | -0.1 | - | - | - | - |
| Pretax Income | -61.2 | -28.65 | -58.74 | -71.83 | -17.99 | -4.35 |
| Income Tax Expense | 0.07 | 0.07 | 0.05 | - | - | - |
| Net Income | -61.28 | -28.72 | -58.79 | -71.83 | -17.99 | -4.35 |
| Net Income to Common | -61.28 | -28.72 | -58.79 | -71.83 | -17.99 | -4.35 |
| Shares Outstanding (Basic) | 5 | 1 | 1 | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | 5 | 1 | 1 | 1 | 1 | 1 |
| Shares Change (YoY) | 589.85% | 4.70% | 11.80% | 8.60% | 3.59% | - |
| EPS (Basic) | -11.42 | -35.78 | -76.67 | -104.73 | -28.49 | -7.13 |
| EPS (Diluted) | -11.42 | -35.78 | -76.67 | -104.73 | -28.49 | -7.13 |
| Free Cash Flow | -52.27 | -50.69 | -57.13 | -17.03 | -13.83 | -3.45 |
| Free Cash Flow Per Share | -9.74 | -63.14 | -74.51 | -24.83 | -21.89 | -5.65 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
| Operating Margin | -2344.68% | -91.58% | -1213.32% | -2660.94% | - | - |
| Profit Margin | -2355.86% | -85.75% | -1192.21% | -3587.66% | - | - |
| Free Cash Flow Margin | -2009.65% | -151.34% | -1158.55% | -850.55% | - | - |
| EBITDA | -58.57 | -28.41 | -58.67 | -53.02 | -18.2 | -3.4 |
| EBITDA Margin | - | -84.81% | - | - | - | - |
| D&A For EBITDA | 2.41 | 2.27 | 1.16 | 0.25 | 0.07 | 0.01 |
| EBIT | -60.99 | -30.67 | -59.83 | -53.27 | -18.27 | -3.41 |
| EBIT Margin | - | -91.58% | - | - | - | - |
| Revenue as Reported | 2.6 | 33.49 | 4.93 | - | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.